
-
SCYNEXIS NASDAQ:SCYX SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Its lead candidate, ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class. It is currently under review by the FDA as a treatment for vaginal yeast infections and in late-stage development for multiple life-threatening fungal infections in hospitalized patients.
Location: 1 Evertrust Plz Fl 13, New Jersey, 07302-3051, US | Website: www.scynexis.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-12.32M
Cash
68.83M
Avg Qtr Burn
-5.459M
Short % of Float
2.35%
Insider Ownership
2.40%
Institutional Own.
32.08%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Brexafemme (Ibrexafungerp) Details Vulvovaginal Candidiasis, Yeast Infection | Approved Quarterly sales | |
Brexafemme (Ibrexafungerp) Details Fungal infections | Approved Quarterly sales | |
SCY-247 Details Fungal infections | Phase 1 Update |